Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.

被引：0

作者：

Usmani, Saad Zafar

Karlin, Lionel

Benboubker, Lotfi

Nahi, Hareth

San-Miguel, Jesus

Trancucci, Danielle

Qi, Keqin

Stephenson, Tara

Perales-Puchalt, Alfredo

Chastain, Katherine

Chari, Ajai

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Ctr Hosp Lyon Sud, Lyon, France

[3] Ctr Hosp Reg Univ, Hop Bretonneau, Tours, France

[4] Karolinska Univ Hosp Huddinge, Stockholm, Sweden

[5] Univ Navarra, Pamplona, Spain

[6] Janssen Res & Dev, Raritan, NJ USA

[7] Janssen Res & Dev, Titusville, NJ USA

[8] Janssen Res & Dev, Spring House, PA USA

[9] Mt Sinai Sch Med, New York, NY USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8034

引用

页数：1